Navigation Links
Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
Date:11/16/2007

ticipating in assessing bavituximab have extensive experience in conducting mid and late stage cancer studies that adhere to FDA and international standards, and we look forward to working with them to ensure the timely conduct of this important Phase II trial."

Tumor response in this new study will be evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) parameters. The trial is being conducted according to International Conference on Harmonization (ICH) and Good Clinical Practices (GCP) standards.

According to the World Health Organization, metastatic breast cancer is the most commonly diagnosed cancer in women, and is second only to lung cancer as a leading cause of female cancer deaths. The National Cancer Institute estimates that 178,480 U.S. women will be diagnosed with cancer of the breast in 2007 and 40,460 women will die of the disease.

Bavituximab is a monoclonal antibody that binds to a phospholipid called phosphatidylserine that is usually located inside normal cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. Bavituximab is believed to help mobilize the body's immune system to destroy the blood vessels needed for tumor growth and spread. In a Phase lb trial in advanced cancer patients, bavituximab plus chemotherapy appeared to have a safety profile consistent with chemotherapy alone and showed positive signs of clinical activity, achieving objective response or disease stabilization in 50% of the evaluable patients. A protocol for a Phase II trial of bavituximab in combination with the chemotherapy drugs paclitaxel and carboplatin in patients with metastatic breast cancer is currently undergoing regulatory review in India. A protocol for a Phase II trial of bavituximab in combination with the chemotherapy drugs paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) is also under regulatory rev
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...30 SEIU Local 21LA memb...ation Sodexo will hold a rally Tuesday, Dec. 1, 20...eadquarters, 3800 Desire Parkway, New Orleans, to ... disciplinary policies that target employees who a...r. Sodexo employees who clean schools in the Recov...
(Date:11/30/2009)... Study Uses Tent To Simulate High Altitude, Low ...re-USNewswire/ -- Distance runners who live at hig...prove their performance during races in areas that...ho suffer from fatigue, improve their exercise per...simulator? ,, That is the question being studie...
(Date:11/30/2009)..., Nov. 30 The Eject Helmet Removal...d equipment in the Top Fuel, Funny Car, Pro Stock ...al Hot Rod Association (NHRA) Full Throttle Drag R...and Top Alcohol Funny Car drivers in the NHRA Luca...uct that allows medical caregivers at race tracks ...
(Date:11/30/2009)...2009 ― Providing free medications to people ...ves at a relatively low cost for provincial govern...St. Michael,s Hospital in Toronto. , "Many pati...medications because they simply don,t fill their p...lead author and a physician at St. Michael,s Hospi...
(Date:11/30/2009)...v. 30 Reportlinker.com announces t...ts catalogue: ,, Key Players and Innovative St...ingredients, pharma, food and drinks ,, http:...novative-Start-Ups-in-Nutraceuticals-Emerging-stra... ,, Nutraceuticals are bioactive compounds with...
Breaking Medicine News(10 mins):Health News:As H1NI Hits New Orleans in Force: School Custodians to Hold Rally to Call on Contractor to Stop Penalizing Workers Coping With Illness 2Health News:Can Exposure to Low Oxygen Levels Benefit Heart Failure Patients? 2Health News:Can Exposure to Low Oxygen Levels Benefit Heart Failure Patients? 3Health News:Can Exposure to Low Oxygen Levels Benefit Heart Failure Patients? 4Health News:National Hot Rod Association Mandates Eject Helmet Removal System for 2010 2Health News:Coverage of inexpensive drugs may increase length and quality of life after heart attack 2Health News:Reportlinker Adds Key Players and Innovative Start-Ups in Nutraceuticals: Emerging Strategies in Ingredients, Pharma, Food and Drinks 2Health News:Reportlinker Adds Key Players and Innovative Start-Ups in Nutraceuticals: Emerging Strategies in Ingredients, Pharma, Food and Drinks 3Health News:Reportlinker Adds Key Players and Innovative Start-Ups in Nutraceuticals: Emerging Strategies in Ingredients, Pharma, Food and Drinks 4Health News:Reportlinker Adds Key Players and Innovative Start-Ups in Nutraceuticals: Emerging Strategies in Ingredients, Pharma, Food and Drinks 5Health News:Reportlinker Adds Key Players and Innovative Start-Ups in Nutraceuticals: Emerging Strategies in Ingredients, Pharma, Food and Drinks 6
... Finally, the world,s first complete intimacy kit... With all the concerns about STDs being plastered ... leave it to a company called "Safe & Cle...l 9, 2009 -- The world,s first complete intimacy k...
... 8 Today, the U.S. Food and Drug Administration (...(PDAC) conducted a review of the safety and effica...r SEROQUEL XR (quetiapine fumarate) extended-relea...: , , , SEROQUEL XR was shown to be eff...
... programs for delivering optimum value and custome...90% of the nation,s nonprofit academic medical cen...lutions, a leader in delivering healthcare resourc...ated hospitals, representing approximately 90% of ...
...predominance of heartburn among asthma sufferers l...uld be a trigger for the coughing, wheezing and br...ndard practice to prescribe heartburn medication t...l without significant heartburn shows that heartbu...
...l 8 The following was released today by the Ameri...ts have suffered a severe blow in the last week. ...s to redefine marriage and in so doing has jeopard... statement that, "The traditional notion that chil...
...nknown in adults, revs up calorie-burning, experts...s) -- Take note of the brown revolution -- the bro...ups of scientists on two continents have independe...sue is metabolically active and the more of this f...
Other Medicine News:Health News:The World's First Complete Intimacy Kit for Safe and Clean Sex 2Health News:The World's First Complete Intimacy Kit for Safe and Clean Sex 3Health News:FDA Advisory Committee Recommendation on SEROQUEL XR Supplemental New Drug Applications 2Health News:FDA Advisory Committee Recommendation on SEROQUEL XR Supplemental New Drug Applications 3Health News:FDA Advisory Committee Recommendation on SEROQUEL XR Supplemental New Drug Applications 4Health News:FDA Advisory Committee Recommendation on SEROQUEL XR Supplemental New Drug Applications 5Health News:FDA Advisory Committee Recommendation on SEROQUEL XR Supplemental New Drug Applications 6Health News:FDA Advisory Committee Recommendation on SEROQUEL XR Supplemental New Drug Applications 7Health News:University HealthSystem Consortium Names Ascent Healthcare Solutions Supplier of the Year at UHC 2009 Performance Excellence Forum 2Health News:University HealthSystem Consortium Names Ascent Healthcare Solutions Supplier of the Year at UHC 2009 Performance Excellence Forum 3Health News:Heartburn medications do not ease asthma symptoms 2Health News:Heartburn medications do not ease asthma symptoms 3Health News:A Fat That May Keep You Thin 2Health News:A Fat That May Keep You Thin 3
(Date:11/30/2009)...Newswire/ -- Amoena USA Corporation, the worldwide...ponsoring the 4th Annual Breast Cancer Survivors C...nor survivors and the people who helped them throu...with the most inspirational story to tell. ,, A...young mothers who bravely endured treatments; wome...
(Date:11/30/2009)..., November 30 Optoacoustics has an...nnel microphone, the most advanced,optical microph...ance imaging,(fMRI) environments. , The t...ard for fiber,optic microphone technology, providi...ncy adaptive noise cancelling. The FOMRI-III also ...
(Date:11/30/2009)... Intelliject, Inc. today announced... a novel epinephrine auto-injector, in the U.S. an...tis U.S. shall be responsible for manufacturing an...le for the on-going development and for obtaining ...co-promotion rights in the territory. ,, Sanofi...
Breaking Medicine Technology:Amoena and Young Survival Coalition Celebrate Breast Cancer Survivors With Contest and Cruise 2New Generation Noise Cancelling Optical Microphone Paves Way for Advanced Brain and Speech Research 2Intelliject, Inc. Enters Into Licensing Agreement with sanofi-aventis for U.S./Canada Rights to Novel Epinephrine Auto-injector 2Intelliject, Inc. Enters Into Licensing Agreement with sanofi-aventis for U.S./Canada Rights to Novel Epinephrine Auto-injector 3Prix Galien USA Announces 2009 Final Candidates 13441 1Prix Galien USA Announces 2009 Final Candidates 13441 2Cleveland Joins Navvis 26amp 3B Company 53927 1Cleveland Joins Navvis 26amp 3B Company 53927 2Guided care reduces cost of health care for older persons with chronic conditions 53925 1Guided care reduces cost of health care for older persons with chronic conditions 53925 2
...ia Pharmaceuticals presented,positive results toda...onal,HIV protease inhibitor (PI). One study based ... of interaction of SPI-256 with HIV protease,provi...tic barrier to,resistance. The second study conduc...6 is generally safe and well tolerated in humans a...
...harmaceuticals, Inc. today,announced positive Phas...96, a first-in-class aminomethylcycline (AMC). The...l and intravenous (IV) forms of PTK 0796 to,Zyvox(...kin and skin,structure infections (cSSSIs). Parate...endpoint, demonstrating no differences between PTK...
Other Medicine Technology:Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor 2Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor 3Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor 4Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 2Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 3Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 4
...800 is an individually configurable System for dec...e identification via cap recognition is optional) ... clearly organized workflow. The input and output ...ty. The System can simply be loaded with various t...
...mbination of the Aliquoting System RSD 800A with a... turns out in an efficient System and a complete s...all important front-end and back-end features: cen...ation, sample quality control, decapping, barcode ...
...SD 800A is an individually configurable System for...itional tube type identification via cap recogniti...ample tubes in a clearly organized workflow. The i...ffer high capacity. The System can simply be loade...
...00 can sort different specimen in one run. Complex...more and all samples are sorted, decapped and arch... after being given sorting priorities. Optionally ...a Decapping Module can be integrated. Selectively ...
Medicine Products: